Strategy & Commercialization (5)

Challenge A UK company had developed a novel system for urinary drainage that provided a number of benefits for patients and caregivers over current systems. It believed that CE marking would be...

Challenge A research group at a leading research-intensive university had developed a qPCR diagnostic/ prognostic platform for patient stratification in autoimmune diseases which they believed could...

Challenge: Our diagnostics consultants were asked to develop an ex-US business development strategy and identify sources of non-dilutive finance for a well-backed, venture capital-funded diagnostics...

Challenge A leading research institute developing novel approaches for the production of ophthalmic treatments wanted to conduct a market and competitive assessment of the current supplier base and...

Challenge A European research institute wanted to assess the market potential for a novel antibody discovery and screening platform, to enable the development of a commercialization strategy and plan.

Challenge: A publicly traded specialty pharma company was considering acquiring a company developing a prescription product for use by surgeons. We were asked to conduct an assessment of the market...

Challenge An established cancer immunotherapy company needed help with a business plan and valuation for a new company to be setup in collaboration with a major US cancer center

Challenge A major public/private investor in a BRIC territory needed help with an investment strategy for building a nationwide radiopharmaceutical infrastructure and capacity in its home country....

Challenge A major nuclear physics research institute looking to build a capability in nuclear medicine needed support with its R&D plan. Alacrita was engaged to help craft a new R&D strategy.

Challenge: The technology transfer function of a leading cancer research institute needed a development plan for a promising small molecule lead series against a novel anti-invasion/anti-metastasis...

Challenge: An emerging specialty pharma company facing an urgent partnering transaction deadline needed to assess the likely reimbursement and pricing of a new therapy in a crowded haematology...

Challenge: A US medical device company wanted to understand how UK payers would view their technology. They engaged Alacrita to find out.